David Duncan, MD
Neurology · Neptune, NJNPI 1053364430
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 19.5%. Reporting peaked in 2019 at $38,864 and has fallen 88.8% since, to $4,344 in 2025. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 759 payments — averaging $171.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$25K
- Sanofi$19K
- EMD Serono, Inc.$19K
- Genentech USA, Inc.$19K
- Biogen$18K
- E.r. Squibb & Sons, L.L.C.$16K
- plus $14K from 35 others
Across 185 payments — averaging $7501.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$999K
- Novartis$230K
- Roche Products Limited$88K
- Bristol Myers Squibb$38K
- Biogen$29K
- E.r. Squibb & Sons, L.L.C.$3K
What the payments were for
- Consulting fees$42,11032%
- Speaking & faculty fees$67,10951%
- Travel & lodging$5,9025%
- Food & beverage$14,59411%
- Education$7061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$130,421 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 16 | $191,008 |
| Dalfampridine ErDalfampridine | 16 | $3,600 |
| Gabapentin | 34 | $722 |
| Baclofen | 43 | $666 |
| Pregabalin | 14 | $323 |
Paid to pharmacies, not to this prescriber.
Other neurology in Neptune
- Lana Zhovtis RyersonNeptune$56K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.